Download PDF
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2021; 11(03): 204-206
DOI: 10.1055/s-0041-1726688
Case Report

Anti-IgE Monoclonal Antibody in Allergic Bronchopulmonary Aspergillosis Not Responding to Systemic Steroids

Pratibha Sharma
1   Department of Microbiology, AIIMS Raipur, Raipur, Chhattisgarh, India
,
Ranganath T. Ganga 
2   Department of Pulmonary Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disorder caused by Aspergillus fumigatus commonly among patients of bronchial asthma. Early diagnosis is the key to successful management and preventing parenchymal destruction. Most of the patients respond well to systemic steroids. In patients not responding to standard treatment, the other treatment options include pulse steroids, antifungals, immunosuppressants, and omalizumab. But exact indication for each of these is not well established. Here we report a 41-year-old ABPA patient who was not responding to systemic steroids became totally asymptomatic with the administration of omalizumab.

Keywords

allergic bronchopulmonary aspergillosis - aspergillus - omalizumab - prednisolone


Publication History

Article published online:
25 May 2021

© 2021. Nitte (Deemed to be University). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110 (05) 685-692
    CrossrefPubMedGoogle Scholar
  • 2 Hinson KFW, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax 1952; 7 (04) 317-333
    CrossrefPubMedGoogle Scholar
  • 3 Greenberger PA. Clinical aspects of allergic bronchopulmonary aspergillosis. Front Biosci 2003; 8: s119-s127
    CrossrefPubMedGoogle Scholar
  • 4 Kumar R. Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: a clinical and serologic evaluation. Chest 2003; 124 (03) 890-892
    CrossrefPubMedGoogle Scholar
  • 5 Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86 (04) 405-414
    CrossrefPubMedGoogle Scholar
  • 6 Schwartz HJ, Greenberger PA. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 1991; 117 (02) 138-142
    PubMedGoogle Scholar
  • 7 Wark PA, Hensley MJ, Saltos N. et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111 (05) 952-957
    CrossrefPubMedGoogle Scholar
  • 8 Mulliez P, Croxo C, Roy-Saint Georges F, Darras A. Allergic broncho-pulmonary aspergillosis treated with voriconazole. Rev Mal Respir 2006; 23 (1 Pt 1) 93-94
    CrossrefPubMedGoogle Scholar
  • 9 Thomson JM, Wesley A, Byrnes CA, Nixon GM. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41 (02) 164-170
    CrossrefPubMedGoogle Scholar
  • 10 Laoudi Y, Paolini JB, Grimfed A, Just J. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA?. Eur Respir J 2008; 31 (04) 908-909
    CrossrefPubMedGoogle Scholar
  • 11 Avila PC. Does anti-IgE therapy help in asthma? Efficacy and controversies. Annu Rev Med 2007; 58: 185-203
    CrossrefPubMedGoogle Scholar
  • 12 Infar D, Crameri R, Lamers R, Achatz G. Molecular and cellular targets of anti-IgE antibodies. Allergy 2005; 60 (08) 977-985
    CrossrefPubMedGoogle Scholar
  • 13 Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354: 2689-2695
    CrossrefPubMedGoogle Scholar
  • 14 van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62 (03) 276-277
    CrossrefPubMedGoogle Scholar